Filtered By:
Condition: Bleeding
Infectious Disease: Coronavirus
This page shows you your search results in order of date.
Order by Relevance | Date
Total 66 results found since Jan 2013.
Cerebral venous thrombosis in patients with autoimmune disease, hematonosis or coronavirus disease 2019: Many familiar faces and some strangers
CONCLUSION: A systematic understanding of particular risk factors that should not be neglected when unconventional cerebral venous thrombosis occurs and for a scientific understanding of pathophysiological mechanisms, clinical diagnosis, and treatment, thus contributing to knowledge on special types of venous stroke.PMID:37365966 | DOI:10.1111/cns.14321
Source: CNS Neuroscience and Therapeutics - June 27, 2023 Category: Neuroscience Authors: Yifan Zhou Huimin Jiang Huimin Wei Xuechun Xiao Lu Liu Xunming Ji Chen Zhou Source Type: research
Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial
CONCLUSIONS: The study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis did not appear to reduce a composite end point of venous and arterial thrombotic events, hospitalization, and death.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04508023.PMID:37154020 | DOI:10.1161/CIRCULATIONAHA.123.063901
Source: Circulation - May 8, 2023 Category: Cardiology Authors: Gregory Piazza Alex C Spyropoulos Judith Hsia Mark Goldin William J Towner Alan S Go Todd M Bull Stephen Weng Concetta Lipardi Elliot S Barnathan Marc P Bonaca PREVENT-HD Investigators Source Type: research
Readmission Risk after COVID-19 Hospitalization: A Moderation Analysis by Vital Signs
CONCLUSIONS: Comorbid conditions, including pulmonary and cardiovascular disease, are associated with readmission risk after COVID-19 hospitalization. The normalization of vital signs within 24 hours of discharge during COVID-19 hospitalization may be an indicator of readiness for discharge and may mitigate some readmission risk conferred by comorbid conditions.PMID:36318952 | PMC:PMC9612414 | DOI:10.14423/SMJ.0000000000001472
Source: Southern Medical Journal - November 1, 2022 Category: General Medicine Authors: Arkadiy Finn Joshua R Tanzer Atin Jindal Vijairam Selvaraj Bradley Collins Kwame Dapaah-Afriyie Source Type: research
